Yung Shin Pharmaceutical partnered with Acer Medical to extend patient access of AI-assisted bone density abnormality screening.

In 2023, Yung Shin Pharmaceutical signed a memorandum of understanding (MOU) with Acer Medical to become strategic partners to jointly promote Acer Medical's smart medical device VeriSee DR (AI-assisted diagnosis of diabetic retinopathy) through hospital channels. And starting in 2024, the cooperation channels will be expanded to clinics and pharmacies, and VeriOsteo OP (AI-assisted bone density abnormality screening software) will be added as a newly added item.

Yung Shin Pharmaceutical is committed to providing high-quality pharmaceuticals and developing diversified products to engage in caring for the public's health. We spare no effort in developing and launching new products to cover major diseases, including diabetes, hyperlipidemia, hypertension, and osteoporosis. With the same pharmaceuitcal high-standard, we also produce health-related products, including brands like HAC, J'FANCY, and Fountain, aiming to provide not only therapeutic drugs but also health supplements for the general public.

Acer Medical's VeriOsteo OP (AI-assisted bone density abnormality screening software) received approval from the Ministry of Health and Welfare's Food and Drug Administration (TFDA) by the end of 2023. It is the first smart medical device to use chest X-rays to screen for bone density abnormalities. It can assist in screening for bone density abnormalities and address the long-term trend of Taiwan's aging population. Yung Shin Pharmaceutical's orthopedic care products, such as cartilage nutrients, calcium supplements, vitamin D3, and osteoporosis drugs, etc., can provide early screening and health care planning for the public, safeguarding their health and quality of life.